This study lasts for 52 weeks and is testing a medicine called **ritlecitinib** in people with a skin condition called **nonsegmental vitiligo**. Vitiligo is when the skin loses its color, and nonsegmental means it happens on both sides of the body. The study is **randomized, double-blind, and placebo-controlled**, meaning neither the participants nor the researchers know who gets the medicine or a look-alike pill called a placebo.

**Key Points:**

• The study lasts a year, and participants need to stop other vitiligo treatments during this time.
• Participants must be 12 or older, and have active or stable nonsegmental vitiligo.
• Participants need to stay on any other medications they are taking without changes.

Participants must be healthy enough to join and can't have certain other health problems or infections. They will have tests and checks to make sure the new medicine is safe and effective. If you're interested and meet the criteria, you may help find a new treatment for vitiligo.